TSO3 — Investor Presentation (August 2017)
32 slides from TSO3's investor presentation, August 2017
Slide 1: To Create and Deliver the New Standard of Care in Sterile Reprocessing
To Create and Deliver the New Standard of Care in Sterile Reprocessing™ Corporate Presentation | August 2017 1
Slide 2: Important Cautions Regarding Forward Looking Statements and Other Disclosures
Important Cautions Regarding Forward Looking Statements and Other Disclosures The statements contained in this presentation and oral statements made by representatives of TSO3 Inc. (“Company”) relating to matters that are not historical facts are forward-looking statements that involve certain risks
Slide 3: Vision. Purpose. To Create and Deliver the New Standard of Care
VISION. PURPOSE. To Create and Deliver The New Standard of Care In Sterile Reprocessing™ A Sterile Device for Every Procedure 3
Slide 4: Major Milestones Laying Foundation for Growth
Major Milestones Laying Foundation for Growth 1998 - 2008 2009-2014 2015 2016 2017 • Founded • Product redesign • Exclusive distribution • Shipped 110 • Added several major • HQ: Québec City, • Introduced STERIZONE® agreement with Getinge - STERIZONE® VP4 Sterilizers medical institutions to Canada 1
Slide 5: STERIZONE VP4 Sterilizer
STERIZONE® VP4 Sterilizer Advantages Dynamic Sterilant Delivery System™ • Single cycle – easy to use, error free cycle Proprietary Technology automatically adjusts the selection sterilant quantity based on load composition, • Mixed load sterilization weight and temperature. • Up to 75 Ib in a single
Slide 6: Protected Breakthrough Technologies: Patents and Patents Pending Worldwide
Protected Breakthrough Technologies /// 138 Patents + 47 Patents Pending Worldwide 1. Insert Room Temperature Instruments Into a Warm Chamber 2. Create a Vacuum and Inject Small Amounts of Vapourized Heated Sterilant Over Time 3. Micro Condensation Forms on the Instruments Dynamic Sterilant Delivery
Slide 7: A Sterile Device for Every Procedure
PURPOSE A Sterile Device for Every Procedure 7
Slide 8: Aging Population – Driving Growth in MIS
Aging Population – Driving Growth in MIS Driving Growth in MI Surgeries and Endoscopies Growth in U.S. Population Age Groups 65+1 Over 90,000,000 65 Years 80,000,000 70,000,000 Old 60,000,000 50,000,000 40,000,000 88% of ophthalmology surgeries 30,000,000 20,000,000 70% of cardiothoracic surgeries 1
Slide 9: Increasing Demand for MIS and Endoscopy Procedures
Increasing Demand for MIS and Endoscopy Procedures Minimally Invasive Surgery (MIS) Aging population expected to • Effective result in increasing demand for • Faster Recovery minimaally invasive diagnostic • More profitable and surgical procedures (MIS) and associated devices Patients age 65+ curren
Slide 10: Health Care Procedures
Health Care Procedures Surgical – OR Support • $6b+ Sterilization Existing Market1 • High Growth Low Temperature Component Millions of Surgical and Diagnostic Procedures Each Year Diagnostic – GI • 50m+ Procedures/year2 • No sterilization for most 1) Market and Market, June 2016 2 )Becker’s GI & End
Slide 11: OR Market: Sterile Devices
OR Market: Sterile Devices Cost Effectiveness Convenience/Simplicity Throughput TSX:TOS 11
Slide 12: A Better Solution
A Better Solution Old Technology TSO3 Technology • 20+ year-old core • Next generation industry technology technology • Single sterilant • Dual Sterilant • Fixed delivery • Dynamic Delivery • Small loads • Simple Single Cycle Operation • Segregated loads • Large Loads • Expensive Sterrad® NX Sterrad
Slide 13: Larger, Mixed Loads
Larger, Mixed Loads Competition VS STERIZONE® VP4 Sterilizer TSX:TOS 13
Slide 14: Health Care Procedures
Health Care Procedures Surgical – OR Support • $6b+ Sterilization Existing Market1 • High Growth Low Temperature Component Millions of Surgical and Diagnostic Procedures Each Year Diagnostic – GI • 50m+ Procedures/year2 • No sterilization for most 1) Market and Market , June 2016 2 )Becker’s GI & En
Slide 15: Diagnostic GI/Endoscopic Market Driver
Diagnostic GI/Endoscopic Market Driver A Shift to a New Standard of Care: Patient Safety TSX:TOS 15
Slide 16: Not Sterile – Why?
Not Sterile – Why? Spaulding Classification TSX:TOS 16
Slide 17: A New Problem: Endoscopes and Superbugs
A New Problem: Endoscopes and Superbugs “Deaths from Drug-Resistant Infections Set to Skyrocket” Deaths from antimicrobial resistant infections and other causes in 20501 Two million+ Americans suffer Carbapenem-resistant CRE infections are linked to Inadequately-cleaned endoscopes annually from anti
Slide 18: How Change Happens
How Change Happens Patient and Medical Technology Facility Demand Advancement • Patient Safety • STERIZONE® VP4 Sterilizer • Litigation • Cost Reduction = Market Change Regulatory Change • FDA Regulation Advancement • Industry Dialogue and Guidelines TSX:TOS 18
Slide 19: Public Awareness
Public Awareness Nation World Los Angeles Times HealthLeaders Media “FDA links ‘superbug‘ to key medical “Jury orders Olympus to pay $6.6 “Infection fears prompt Fujifilm device.“ million but rejects claims its medical Medical Systems Duodenoscopes scopes are unsafe.“ recall.” “LOS ANGELES — A ‘supe
Slide 20: Industry Call-to-Action
Industry Call-to-Action “Despite reprocessing in accordance with “…Despite adherence to strict “We have to transition to sterilization. That is US guidelines, viable microbes and biologic guidelines…bacteria can at times remain on the only way we’ll eliminate the outbreaks debris persisted in clinic
Slide 21: Modernizing GI Endoscope Reprocessing
Modernizing GI Endoscope Reprocessing Old TSO3 STERIZONE® VP4 Sterilizer TSX:TOS 21
Slide 22: Shift is Happening
Shift is Happening Dirty Endoscopes Raising A 21st Century Nosocomial Deadly Bacteria On Seattle Hospital Sues Alarms for Colonoscopies Issue With Endoscopes Medical Scopes Trigger Olympus Over Superbug Infections Outbreak 2009 2013 2014 2014 2015 2015 2015 2015 2015 VA Officials Get Probed For Dirt
Slide 23: Shift is Happening
Shift is Happening Cross-contamination More Infections From Dirty Endoscopes An Epidemic Is On Hospitals Failing to Not Limited to Contaminated Top ECRI Institute's the Rise That May Kill Report Outbreaks Duodenoscopes Scopes Suspected in 2016 Technology More People Each Due to Contaminated L.A. Haz
Slide 24: Shift is Happening
Shift is Happening Why It Took Years For The Superbug Infections Must Redesigned Olympus Carbapenem-Resistant FDA to Warn About Be Listed On Death Scopes linked to Superbug Enterobacteriaceae in Patients From Infections Tied to Medical Certificate Under Proposed Outbreak: 7 Things to Know the US Vet
Slide 25: Industry First: FDA Clearance of TSO Endoscope Claims
Industry First: FDA Clearance of TSO Endoscope Claims 3 CLEARED Video Colonoscope The only FDA cleared device validated to sterilize colonoscopes, gastroscopes and other flexible endoscopes up to 3.5m in length and with four or fewer channels. Video Gastroscope TSX:TOS 25
Slide 26: Duodenoscopes – The Point on the Spear
Duodenoscopes – The Point on the Spear Duodenoscope Expanded Claims: FDA – Duodenoscopes • Already cleared in Canada & Europe • Launched regulatory filings with US regulators for duodenoscopes; goal to receive US clearance by end of 2017 Market Launch and Awareness • Lead hospitals/jurisdictions in
Slide 27: Commercialization
Commercialization Joacim Lindoff President of Surgical Workflows Getinge Group • Getinge Group - Exclusive Global Distributor • Global sales & service; 3,000+ associates in 36 countries • Paid US$7.5 million up-front license fee “The STERIZONE® VP4 Sterilizer uniquely • Minimum annual purchase commi
Slide 28: Marketing Materials
Marketing Materials Fractional Print Ad Series TSX:TOS 28
Slide 29: Summary
Next Generation Technology Extensive Patent Portfolio Razor/Razorblade Business Model FDA-cleared Device for Terminal Sterilization of Colonoscopes SUMMARY and other flexible endoscopes1 Global Distribution Partner Growing Sales Financially Sound TSX:TOS 1) Up to 3.5 meters in length and with four o
Slide 30: Key Stats (TSX: TOS)
Key Stats (TSX: TOS) /// All Dollars in USD, Unless Noted Otherwise Stock Price (8/1/17) CAD$3.17 Quarterly Revenue Growth 52 Week High-Low CAD$3.73-$2.20 US$ Millions $4.6 Shares Outstanding (mrq) (no warrants) 92.7M $4.2 Average Daily Volume (90 day) 234,776 $3.7 Market Capitalization CAD$294M $3.
Slide 31: Contact Us
TSO3 Inc. - Canada TSO3 Corporation - US CONTACT US 2505 Avenue Dalton Québec, Québec 1636 American Way Myrtle Beach, SC 29577 G1P 3S5 CANADA Tel (418) 651‐0003 info@tso3.com Investor Relations Ron Both Barry Mire Vice President Managing Partner Renmark Financial Communications Inc. CMA Tel (416) 64
Slide 32: T Sh,
T Sh,